SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high conviction as Dr. PSS's recent presentation on Anktiva's potential to prevent and cure cancer sparks widespread community excitement, fueling intense short squeeze speculation and institutional interest amidst perceived regulatory resistance.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is experiencing a notable surge amid widespread reports of potential takeover interest from multiple rivals, with community discussion focusing on the company's deeply undervalued assets and strong free cash flow as catalysts for a potential bidding war and short squeeze.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending with notable pre-earnings strength, fueled by expectations of an 18th consecutive beat and raise and the continued integration of its OpenAI partnership into its AI marketing platform. Community sentiment is divided between strong bullish conviction in its proprietary data moat and concerns over broader software sector headwinds potentially leading to a "sell the news" event.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors anticipate upcoming earnings, with community discussion centered on its strategic pivot to AI and high-performance computing data centers, substantial backing from Google, and a notable short interest. Many believe these factors position the company for a significant short squeeze and long-term growth in the burgeoning AI infrastructure sector.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday (WDAY) is trending after its latest earnings release, which, despite beating estimates, triggered a significant aftermarket sell-off amidst concerns about future subscription growth and mixed reactions to its AI acquisition strategy and recent leadership changes. The community is sharply divided, with bulls viewing the dip as a buying opportunity while bears contend that AI disruption fundamentally challenges the SaaS business model, anticipating further declines for the enterprise software giant.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following a significant strategic collaboration with Astellas for its VIR-5500 prostate cancer asset, bolstered by positive Phase 1 trial data and multiple analyst upgrades. The community is actively discussing the substantial financial commitment and the potential for a short squeeze, given the tight float and notable short interest.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited (ANPA) is trending due to its acquisition of TikTok icon Khaby Lame's core company, sparking community excitement about potential explosive growth in digital content. However, the move is also drawing significant skepticism and warnings of a pump-and-dump, with many questioning its valuation compared to fundamentals.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as a key director's substantial insider purchase and a new LPGA marketing partnership signal strong long-term confidence, even while the community debates its undervalued status, the impact of increased growth-oriented expenses, and ongoing buyout speculation.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining, now known as Cipher Digital, is trending following its Q4 earnings call which confirmed a strategic pivot to HPC data centers, revealing billions in contracted revenue with hyperscalers and an expanding pipeline. This news is driving bullish sentiment and discussions of a significant re-rating, despite a reported net loss largely attributed to non-cash items during the transition.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as the community eagerly anticipates its Q3 earnings, with discussions focused on updated guidance and the potential impact of a recent FDA safety notice regarding specific product lots. Persistent speculation surrounds a possible short squeeze or outright acquisition, fueled by the stock's perceived undervaluation and strategic repositioning, despite ongoing frustrations with its price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In its bid to add more mortgage options to its platform, Opendoor acquired homebuyer.com, a mortgage data platform, in Dec. last year.&nbsp;</li><li>OPEN’s CEO said that the company shipped its latest feature late Thursday.&nbsp;</li><li>The real estate digital platform on Thursday posted revenue for the fourth-quarter (Q4) of $736 million, much above street expectations of $591.75 million, as per data from Fiscal.ai.</li></ul>OpenDoor's (<a href="https://stocktwits.com/symbol/OPEN">OPEN</a>) Chief Executive Officer Kaz Nejatian in an exclusive interview to Stocktwits on Friday hinted that the company's mortgage product is in beta phase as the company pushes to enable itself to issue its own mortgage on homes it sells, helping cut out middlemen.“I left the earnings call and came to the office and started working on our product because we actually shipped a new feature late last night around 11 p.m. So I was up a little late shipping,” Nejatian told Stocktwits’ in an <a href="https://stocktwits.com/symbol/OPEN/event/f9cbb7c3-0777-4d00-8179-249bbbf2628b">interview</a>.&nbsp;In its bid to add more mortgage options to its platform, Opendoor acquired homebuyer.com, a mortgage data platform, in Dec. last year. The deal fits OPEN’s CEO Kaz’s AI-pilled vision of using data to eliminate ‘toilful work’ like manual paperwork.<h2 class="st-heading-2">Critical Of Fed</h2>Nejatian criticized the U.S. Federal Reserve for maintaining the interest rates at the level they are.&nbsp;“I think the Fed is being deeply irresponsible these days with maintaining these interest levels,” he told Stocktwits.&nbsp;“Trueflation, which is a much better measure of inflation than CPI, truflation has been sub 1 % basically the entire year. The Fed is asking people to believe that Bureau of Labor Statistics’ (BLS) data is a more reliable source for inflation and what's happening to the economy than truflation. And no one believes that. There's no one who invests their own money who would look at BLS data,” he added.&nbsp;The Federal Reserve kept the benchmark interest unchanged at 3.5%-3.75% in its January meeting. The latest Federal Open Market Committee’s (FOMC) minutes released by the Fed earlier this week revealed that the central bank might hike the interest rates if inflation does not come down to its targeted range.&nbsp;“I think it is highly irresponsible to have artificially elevated interest rates at this time. And I think they need to do something because this is just like, it's very odd,” Nejatian further added.&nbsp;<h2 class="st-heading-2">Q4 Earnings</h2>The real estate digital platform posted revenue for the fourth-quarter (Q4) of $736 million, much above street expectations of $591.75 million, as per data from Fiscal.ai. Meanwhile, the company’s loss per share came in at $1.26, trailing market expectations of a loss per share of $0.11.Opendoor said that it expects Q1 revenue to decrease approximately 10% quarter-over-quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OPEN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have risen 221% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Kaz Nejatian, CEO, Opendoor, speaks onstage during "At the Builder's Table: Building Successful Businesses" panel in Atlanta, Georgia.

Exclusive: Opendoor CEO Reveals Company’s Own Mortgage Product Is In Beta Phase, Criticizes Fed On Interest Rates

OPEN’s CEO Kaz Nejatian said that truflation is a much better measure of inflation and no one who invests their own money looks at BLS data. 

Equity

OPEN’s CEO Kaz Nejatian said that truflation is a much better measure of inflation and no one who invests their own money looks at BLS data. 


<ul class="summary-bullets"><li>Palantir’s software will also run in Rackspace’s Private Cloud and U.K. Sovereign data centers.</li><li>Rackspace plans to increase the number of engineers trained on Palantir’s technologies to more than 250 over the next year from 30 currently.</li><li>The companies expect the partnership to significantly shorten AI deployment timelines.</li></ul>Shares of Rackspace Technology (RXT) extended their gains after the opening bell on Wednesday, building on a more than twofold surge in pre-market trading, after the company announced a partnership with Palantir Technologies (PLTR) to help enterprises rapidly deploy Palantir’s Foundry and Artificial Intelligence Platform.At the time of writing, <a href="https://stocktwits.com/symbol/RXT">RXT shares</a> were up 275%, while <a href="https://stocktwits.com/symbol/PLTR">PLTR stock</a> climbed 4.7%.<h2 class="st-heading-2">Rackspace To Deploy Palantir Software In UK</h2>As part of the agreement, Palantir’s software will also run in Rackspace’s Private Cloud and U.K. Sovereign data centers. Rackspace currently has 30 engineers trained on Palantir’s technologies to assist with data migration and complex deployments, and plans to expand that number to more than 250 over the next year. The companies expect the partnership to significantly shorten AI deployment timelines.“Palantir’s platform, combined with Rackspace's governed cloud operations and our shared forward-deployed engineering approach, enables customers to accelerate time to value and drive competitive business impact with governance and security. This is especially important in regulated industries,” said Gajen Kandiah, CEO of Rackspace Technology.&nbsp;<h2 class="st-heading-2">Rackspace’s VMware Sovereign Cloud Partner Status</h2>Last month, Rackspace Technology announced that its U.K. Sovereign Services cloud platform earned VMware Sovereign Cloud Partner Status, confirming that it meets data sovereignty standards. The company said the designation validates its ability to comply with national privacy and security regulations.The company’s Sovereign Services platform offers a fully managed private cloud built on VMware technologies and operated from U.K.-based data centers. The platform serves public-sector agencies, financial services, and healthcare services.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits changed to ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/RXT_jpg_0a659176f3.webp" alt="RXT.jpg">One user commented saying it’s the “right partnership” and a “buyout target.”<stembedurl>https://stocktwits.com/stockjock2424/message/645242737</stembedurl>Another user expects the stock to climb to $1.90 if it breaks past the $1.70 resistance. RXT stock is currently trading at around $1.5.<stembedurl>https://stocktwits.com/tmpalider/message/645242734</stembedurl>The stock has gained around 50% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

RXT Stock Soared 275% Today – What’s The Connection With Palantir?

The company announced it would help businesses rapidly deploy Palantir’s Foundry and Artificial Intelligence Platform.

<ul class="summary-bullets"><li>The company also said it expects $10 million to $20 million in adjusted EBITDA in FY2027.&nbsp;</li><li>The company said for the third quarter its revenue was $16.3 million versus $40.7 million in the prior-year quarter, a 60% decrease.</li><li>Direct Operating Margin was 69%, compared to 48% in the prior year quarter, reflecting the company's continued focus on cost management.&nbsp;</li></ul>Shares of Cineverse (<a href="https://stocktwits.com/symbol/CNVS">CNVS</a>) jumped on Tuesday after it posted higher-than-expected outlook for its FY 2027 revenue.&nbsp;The company said it expects $115 million to $120 million in revenue for fiscal year 2027, that commences from April 1, 2026. Analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai.&nbsp;The company also said it expects $10 million to $20 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in FY2027.&nbsp;"Already, we have seen extremely positive results from the Giant acquisition over the last 6 weeks, and IndiCue's month-over-month financial performance prior to acquisition was scaling up very rapidly. Therefore, we feel very confident in the financial guidance we are issuing for Fiscal Year 2027, which begins April 1, 2026, of $115 to $120 million in Revenue and $10 to $20 million in Adjusted EBITDA," said Chris McGurk, Cineverse Chairman and CEO.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>The company said for the third quarter its revenue was $16.3 million versus $40.7 million in the prior-year quarter, a 60% decrease, due to approximately $22.8 million of theatrical revenue from Terrifier 3 in the prior year fiscal quarter. The revenue was also below analysts’ estimates of $20 million, as per data from fiscal.ai.&nbsp;Direct Operating Margin was 69%, compared to 48% in the prior year quarter, reflecting the company's continued focus on cost management.&nbsp;The company said its total streaming viewers increased approximately 10% year-over-year in Q3 FY26 to 149 million.&nbsp;The company’s net loss attributable to common stockholders was $1.0 million, or $0.05 per basic and diluted share, compared to a net profit of $7.0 million, or $0.34 per share, in the prior-year quarter. Analysts expected a loss of $0.03 per share.&nbsp;"Our financial objective during this quarter was to focus on improving operating results in our base business in anticipation of closing the transformative Giant and IndiCue acquisitions. We are very pleased that these efforts paid off, with significant increases in both Direct Operating Margins and Adjusted EBITDA,” said McGurk.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around CNVS trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 36.4% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/new-york-times-sahres-are-rallying-what-is-the-connection-with-berkshire-hathaway/cZRWySkR4H3">NYT Stock Is Rallying After-Hours – What Is The Berkshire Hathaway Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of Cineverse jumped on Tuesday after it posted higher-than-expected outlook for its FY 2027 revenue. 

Why Is Cineverse Stock Rising Despite Missing Q3 Revenue and Earnings Estimates?

The company said it expects $115 million to $120 million in revenue for fiscal year 2027, however analysts on average were expecting the revenue of $85.23 million, as per data from fiscal.ai. 

<ul class="summary-bullets"><li>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024.</li><li>Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024.</li><li>The company said strong financial performance in the third quarter was led by the Capital Markets segment.&nbsp;</li></ul>BRC Group Holdings, formerly known as B.Riley Financial, rallied in after-market hours on Wednesday after it announced its delayed quarterly results.&nbsp;The company filed financial reports for three quarters within 120 days, achieving NASDAQ compliance ahead of the deadline, it said in a regulatory filing.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024. The company said basic and diluted earnings per common share were $2.91 compared to a loss per share of $9.39 in the third quarter 2024.Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024. The company said strong financial performance in the third quarter was led by the Capital Markets segment with $65.4 million in services and fee revenues, the highest quarterly total since the fourth quarter of 2023.“We are pleased with the third quarter financial results. B. Riley Securities had a very strong quarter across investment banking, advisory, and research and trading with equity and debt capital raises totaling approximately $10.5 billion while delivering product innovation,” Bryant Riley, Chairman and Co-Chief Executive Officer of BRC, said.&nbsp;“Our Communications segment produced strong cash flow, consistent with previous quarters. B. Riley Wealth enhanced products and services for clients, while reducing costs and integrating its back office,” he added.&nbsp;<h2 class="st-heading-2">B.Riley Woes</h2>BRC’s struggles to file timely earnings reports started after a turbulent period in 2024 when it grappled with soured investments, flaws in financial reporting and a U.S. civil investigation.Franchise Group was a key investor of BRC and its bankruptcy in late 2024 left B. Riley burdened with write-offs of hundreds of millions of dollars and it was unable to file its annual and quarterly reports with US regulators on a timely basis. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One user predicted the stock could hit $15 on Thursday.<a href="https://stocktwits.com/SelectiveTrader/message/641848445">https://stocktwits.com/SelectiveTrader/message/641848445</a>Shares of RILY have jumped 53% over the past year.&nbsp; &nbsp;

Chairman, B. Riley & Co. Bryant Riley (L) and CEO, B. Riley & Co. Tom Kelleher. (Photo by Matt Winkelmeyer/Getty Images)

B.Riley Stock Soars Nearly 40% - What’s Behind The Move?

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 

<ul class="summary-bullets"><li>As part of the deal, Bitfarms will receive $9 million in cash upon closing, expected in Q1 2026.</li><li>The CEO said the deal brings forward an estimated 2 to 3 years of free cash flow from operations to be reinvested in our North American HPC/AI energy infrastructure in 2026.</li><li>Bitfarms plans to wind down its Bitcoin mining operations by 2027.</li></ul>Shares of bitcoin miner Bitfarms (<a href="https://stocktwits.com/symbol/BITF">BITF</a>) jumped more than 4% in premarket trading on Friday after it announced that it has entered into a definitive share purchase agreement to sell its 70 MW site in Paso Pe, Paraguay, to the Sympatheia Power Fund (SPF), a crypto infrastructure fund managed by Singapore-based Hawksburn Capital.The deal is valued at $30 million. Bitfarms will receive $9 million in cash upon closing, expected in Q1 2026, and up to $21 million over 10 months following closing, based on certain payment milestones, it stated.The sale of Paso Pe is the culmination of a series of transactions to completely exit LatAm and refocus the company, its management team, and capital on 100% North American power and infrastructure for HPC/AI.“This transaction brings forward an estimated two to three years of anticipated free cash flows from operations to be reinvested into our North American HPC/AI energy infrastructure in 2026,” Ben Gagnon, CEO at Bitfarms, said.<h2 class="st-heading-2">Pivot to HPC</h2>Bitfarms’ pivot into high-performance computing (HPC) and AI infrastructure comes at a time when crypto miners are increasingly struggling to make a profit as energy costs climb and Bitcoin has been showing weakness and thus are adapting to changing market conditions.It’s also not the only company to pivot towards artificial intelligence and high-performance computing. Several firms, including Core Scientific (CORZ), Iren (IREN), Hive Digital (HIVE), and Terawulf (WULF), have also announced similar strategic moves.Bitfarms plans to wind down its Bitcoin mining operations by 2027, and its transition will begin with its 18-megawatt site in Washington State. The company had said the facility would be converted into a liquid-cooled GPU facility designed for Nvidia’s next-generation GB300s.As part of its pivot, its CEO had <a href="https://stocktwits.com/news-articles/markets/equity/bitfarms-slumps-after-q3-miss-ceo-reaffirms-ai-pivot-with-nvidia/cLP92RaRE3m">stated</a> that the company is converting its Washington site and other assets to support AI workloads and cloud operations, backed by the company’s recent $588 million financing round. The core of the plan centers on NVIDIA’s next-generation Vera Rubin GPUs, expected to launch in Q4 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BITF trended in ‘extremely bearish’ territory amid ‘low’ message volumes.<img src="https://news.stocktwits-cdn.com/bitf_PNG_62282e1d56.webp" alt="bitf.PNG">For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bitfarms logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

From Bitcoin Mining To AI: What’s Driving BitFarms’ Stock Jump Today?

BitFarms agreed to sell its 70 MW site in Paraguay to a crypto infrastructure fund for $30 million as part of its plans to fully exit LatAm.

What’s Driving BitFarms’ Stock Jump Today

BitFarms agreed to sell its 70 MW site in Paraguay to a crypto infrastructure fund for $30 million as part of its plans to fully exit LatAm.


<ul class="summary-bullets"><li>The sale positions the company to reinvest capital in its core higher-growth segments, OSS said.&nbsp;</li><li>Bressner acquired Bressner for about $5.6 million in October 2018.&nbsp;</li><li>The company now expects revenue of $30 million to $32 million for the full year, marking year-over-year growth of 22% to 30%, in light of the transaction. &nbsp;</li></ul>Shares of One Stop Systems (OSS) jumped 6% after hours on Tuesday after the company announced the sale of all assets and operations of Bressner Technology GmbH and updated its full-year revenue outlook following the transaction.Hardware manufacturer OSS sold Bressner, which it acquired in October 2018, for $22.4 million to Hiper Euro GMBH on Tuesday. The sale positions the company to reinvest capital in its core higher-growth segments including deployable AI, real-time sensor processing, and rugged edge systems engineered for mission-critical defense and commercial environments, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/30/3211590/0/en/OSS-Announces-the-Sale-of-Bressner-Technology-GmbH-to-Hiper-Euro-GMBH.html">said.</a>Alongside the divestment, the company said it now expects revenue of $30 million to $32 million for the full year, marking year-over-year growth of 22% to 30%. OSS in November had said that it expects full-year consolidated revenue of $63 million to $65 million, including OSS segment revenue of $30 million to $32 million.<h2 class="st-heading-2">Pivot Into Higher-Growth Segments</h2>Bressner acquired Bressner for about $5.6 million and since then, Bressner has increased annual sales from approximately $18.3 million in 2019 to nearly $33 million on a trailing 12-month basis as of September 30, 2025, the company said.OSS President and CEO Mike Knowles termed the transaction an “important milestone” in the company’s evolution.“With a more focused, streamlined and simplified business, we expect to end 2025 with a significant cash position, no debt, strong year-over-year sales growth, and higher gross margin. We believe these actions establish a powerful foundation to deliver multi-year organic revenue growth of over 20%, higher gross margin, and pursue complementary opportunities that add new customers, technologies, and solutions across our core AI, ML, and edge markets,” Knowles said.<h2 class="st-heading-2">Updated Guidance</h2>Following the transaction, the company now expects positive full year adjusted core profit exclusive of the one-time pre-tax gain of nearly $7.4 million associated with the Bressner transaction.Bressner will be treated as a discontinued operation when the company reports results for the fourth quarter and full year 2025, OSS added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around OSS jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user applauded Tuesday's transaction as “asset-based financing done right.”<stembedurl>https://www.stocktwits.com/Momoware/message/640454421</stembedurl>Another highlighted that the company now has more cash for mergers and acquisitions.<stembedurl>https://www.stocktwits.com/TheBruss/message/640451591</stembedurl><a href="https://stocktwits.com/symbol/OSS">OSS stock</a> has more than doubled this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-starts-cybercab-production-ahead-of-launch-in-2026/cL7IhipREyZ">Tesla Starts Cybercab Production Ahead Of Launch In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the One Stop Systems (OSS) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

One Stop Systems Stock Rises After Hours On Selling Bressner To Focus On Higher-Growth Segments

Hardware manufacturer OSS sold Bressner, which it acquired in October 2018, for $22.4 million to Hiper Euro GMBH on Tuesday.

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

<ul class="summary-bullets"><li>FueCell's fourth-quarter earnings received a boost from strong demand for electricity amidst the global AI push.</li><li>The company’s fourth-quarter revenue surged past estimates.</li><li>It reported a narrower loss in the quarter compared to the year-ago period.</li></ul>FuelCell Energy (<a href="https://stocktwits.com/symbol/FCEL">FCEL</a>) shares jumped 35% at the opening bell on Thursday after its fourth quarter revenue surged past analyst estimates, helped by increasing demand for electricity and data center projects amidst a global AI push, while its loss came in narrower than expected.&nbsp;As corporations and governments continue to adopt and implement artificial intelligence in their daily operations, the demand for data centers and electricity to keep them running has remained high, helping firms like FuelCell, which provide fuel cell power plants that generate clean electricity for businesses and communities.<h2 class="st-heading-2">&nbsp; Q4 Report</h2>The company reported fourth-quarter (Q4) revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai.&nbsp;“We believe that our fourth quarter performance and ongoing cost reductions have positioned us well to meet the accelerating demand for electricity and data center projects in the U.S. and internationally,” said Jason Few, President and CEO of FuelCell Energy.The company also posted an adjusted net loss attributable to common stockholders of $29.8 million in the quarter, compared to an adjusted net loss of $35.3 million in the fourth quarter of fiscal 2024. It reported an adjusted net loss per share of $0.83 compared to analysts’ expectation of a loss of $1.09 per share.&nbsp;<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. The stock is among the top 10 trending tickers on Stocktwits.&nbsp;<figure class="image"><img style="aspect-ratio:636/76;" src="https://news.stocktwits-cdn.com/Capture_3_PNG_f220001d6f.webp" alt="On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. " width="636" height="76"></figure>One of the users on Stocktwits sounded “super bullish” on the stock after its earnings report.<figure class="image"><img style="aspect-ratio:648/109;" src="https://news.stocktwits-cdn.com/Capture2_PNG_cf56df1028.webp" alt="One of the users on Stocktwits sounded “super bullish” on the stock after FuelCell's earnings report." width="648" height="109"></figure>FuelCell Energy shares have declined nearly 24% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp; &nbsp;

In this photo illustration, the FuelCell Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did FuelCell Stock Rocket 35% Today?

The company reported fourth-quarter revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai. 

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

DFAS
Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAS News

DFASDimensional ETF Trust - Dimensional U.S. Small Cap ETF